Clinical Trial Update: A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study [Phase 2]

View source ↗

Summary

Phase II multicenter trial evaluating post-operative concurrent chemoradiotherapy with weekly cisplatin and tislelizumab for high-risk head and neck squamous ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Conditions: Head and Neck Cancer, Radiation | Phase 2 | Status: UNKNOWN